Total Payments
$248,592
2024 Payments
$113,081
Companies
25
Transactions
212
Medicare Patients
538
Medicare Billing
$94,402
Payment Breakdown by Category
Consulting$163,173 (65.6%)
Travel$46,214 (18.6%)
Other$27,804 (11.2%)
Research$6,733 (2.7%)
Food & Beverage$4,654 (1.9%)
Education$13.34 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $163,173 | 57 | 65.6% |
| Travel and Lodging | $46,214 | 66 | 18.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,004 | 6 | 6.0% |
| Honoraria | $11,300 | 4 | 4.5% |
| Unspecified | $6,733 | 6 | 2.7% |
| Food and Beverage | $4,654 | 69 | 1.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,000 | 2 | 0.4% |
| Grant | $500.00 | 1 | 0.2% |
| Education | $13.34 | 1 | 0.0% |
Payments by Type
General
$241,859
206 transactions
Research
$6,733
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma Europe Ltd | $45,633 | 10 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $26,245 | 34 | $0 (2024) |
| Merck Sharp & Dohme LLC | $23,176 | 16 | $0 (2024) |
| PFIZER INC. | $23,006 | 23 | $0 (2024) |
| Astellas Pharma Inc | $20,631 | 11 | $0 (2024) |
| Seagen Inc. | $19,005 | 23 | $0 (2023) |
| EMD Serono, Inc. | $15,593 | 11 | $0 (2024) |
| Astellas Pharma Global Development | $13,338 | 17 | $0 (2023) |
| ABBVIE INC. | $13,064 | 7 | $0 (2024) |
| Gilead Sciences, Inc. | $11,580 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $113,081 | 49 | Astellas Pharma Europe Ltd ($45,633) |
| 2023 | $38,792 | 38 | Merck Sharp & Dohme LLC ($21,118) |
| 2022 | $18,071 | 19 | Astellas Pharma Global Development ($4,491) |
| 2021 | $7,760 | 3 | Astellas Pharma Global Development ($3,100) |
| 2020 | $18,127 | 14 | Seagen Inc. ($7,252) |
| 2019 | $13,679 | 24 | AstraZeneca Pharmaceuticals LP ($6,037) |
| 2018 | $15,937 | 27 | AstraZeneca Pharmaceuticals LP ($13,066) |
| 2017 | $23,145 | 38 | Genentech USA, Inc. ($11,138) |
All Payment Transactions
212 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Astellas Pharma Inc | Padcev (Drug) | Travel and Lodging | Cash or cash equivalent | $12,302.46 | General |
| Category: Oncology | ||||||
| 12/30/2024 | Astellas Pharma Inc | Padcev (Drug) | Travel and Lodging | In-kind items and services | $1,206.61 | General |
| Category: Oncology | ||||||
| 12/30/2024 | Astellas Pharma Inc | Padcev (Drug) | Travel and Lodging | Cash or cash equivalent | $644.86 | General |
| Category: Oncology | ||||||
| 12/30/2024 | Astellas Pharma Inc | Padcev (Drug) | Travel and Lodging | Cash or cash equivalent | $573.23 | General |
| Category: Oncology | ||||||
| 12/30/2024 | Astellas Pharma Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $472.19 | General |
| Category: Oncology | ||||||
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,880.00 | General |
| 11/29/2024 | Astellas Pharma Inc | Padcev (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,183.00 | General |
| Category: Oncology | ||||||
| 11/29/2024 | Astellas Pharma Inc | Padcev (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $85.00 | General |
| Category: Oncology | ||||||
| 11/29/2024 | Astellas Pharma Inc | Padcev (Drug) | Travel and Lodging | Cash or cash equivalent | $46.17 | General |
| Category: Oncology | ||||||
| 11/29/2024 | Astellas Pharma Inc | Padcev (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $38.99 | General |
| Category: Oncology | ||||||
| 10/16/2024 | PFIZER INC. | PADCEV (Biological) | Honoraria | Cash or cash equivalent | $7,700.00 | General |
| Category: Oncology | ||||||
| 10/16/2024 | PFIZER INC. | PADCEV (Biological) | Honoraria | Cash or cash equivalent | $1,400.00 | General |
| Category: Oncology | ||||||
| 10/16/2024 | PFIZER INC. | PADCEV (Biological) | Travel and Lodging | In-kind items and services | $109.33 | General |
| Category: Oncology | ||||||
| 10/16/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $54.96 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Astellas Pharma Europe Ltd | Padcev (Drug) | Consulting Fee | Cash or cash equivalent | $2,550.00 | General |
| Category: Oncology | ||||||
| 10/02/2024 | PFIZER INC. | PADCEV (Biological) | Honoraria | Cash or cash equivalent | $700.00 | General |
| Category: Oncology | ||||||
| 09/23/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,830.00 | General |
| 09/23/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 09/15/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $77.58 | General |
| Category: Oncology | ||||||
| 09/15/2024 | Astellas Pharma Inc | — | Food and Beverage | In-kind items and services | $15.45 | General |
| 09/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $77.86 | General |
| Category: ONCOLOGY | ||||||
| 09/13/2024 | PFIZER INC. | PADCEV (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: PADCEV CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 09/13/2024 | Astellas Pharma Inc | — | Food and Beverage | In-kind items and services | $62.91 | General |
| 08/22/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: BioOncology | ||||||
| 07/11/2024 | Samsung Bioepis Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $1,040.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and Locally Advanced Urothelial Carcinoma Study (mUC) | AstraZeneca Pharmaceuticals LP | $4,426 | 1 |
| A global, multicentre, open-label, randomised Phase II trial of tobemstomig with or without tiragolumab vs atezolizumab in patients with untreated metastatic urothelial cancer ineligible for platinum-based chemotherapy | F. Hoffmann-La Roche AG | $1,196 | 2 |
| PADCEV CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| ASP1941 Phase II Clinical Study A Double-blind, Placebo-controlled, Parallel-group, Dose-response Study in Patients with Type 2 Diabetes Mellitus | Astellas Pharma Global Development | $170.83 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 101 | 188 | $126,321 | $19,522 |
| 2022 | 4 | 135 | 254 | $169,051 | $27,054 |
| 2021 | 4 | 145 | 231 | $165,487 | $26,307 |
| 2020 | 4 | 157 | 263 | $163,302 | $21,519 |
Total Patients
538
Total Services
936
Medicare Billing
$94,402
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 85 | 157 | $121,361 | $18,649 | 15.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 16 | 31 | $4,960 | $873.15 | 17.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 88 | 189 | $146,097 | $22,969 | 15.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 19 | 23 | $4,209 | $1,833 | 43.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $14,105 | $1,468 | 10.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 15 | 29 | $4,640 | $784.52 | 16.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 80 | 159 | $122,907 | $19,558 | 15.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 34 | 38 | $21,926 | $2,719 | 12.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $17,360 | $2,499 | 14.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 15 | 18 | $3,294 | $1,531 | 46.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 81 | 151 | $118,312 | $14,140 | 12.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 37 | 50 | $28,850 | $3,405 | 11.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 17 | 38 | $12,388 | $2,494 | 20.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 22 | 24 | $3,752 | $1,480 | 39.4% |
About Terence Friedlander, MS
Terence Friedlander, MS is a Hematology & Oncology healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1215134267.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Terence Friedlander, MS has received a total of $248,592 in payments from pharmaceutical and medical device companies, with $113,081 received in 2024. These payments were reported across 212 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($163,173).
As a Medicare-enrolled provider, Friedlander has provided services to 538 Medicare beneficiaries, totaling 936 services with total Medicare billing of $94,402. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location San Francisco, CA
- Active Since 07/02/2007
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1215134267
Products in Payments
- Padcev (Drug) $78,383
- PADCEV (Biological) $29,809
- IMFINZI (Drug) $23,412
- Trodelvy (Drug) $11,476
- TECENTRIQ (Biological) $11,199
- KEYTRUDA (Biological) $9,456
- Bavencio (Drug) $5,910
- PADCEV (Drug) $4,286
- INLYTA (Drug) $3,442
- XTANDI (Drug) $2,804
- SUTENT (Drug) $2,220
- IMFINZI (Biological) $2,148
- FOUNDATIONONE LIQUID CDX (Device) $1,750
- FYARRO (Drug) $1,500
- PROVENGE (Drug) $1,452
- Bavencio (Biological) $929.39
- LYNPARZA (Drug) $685.00
- NO PRODUCT DISCUSSED (Drug) $674.66
- Venclexta (Drug) $564.01
- Tecentriq (Biological) $387.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in San Francisco
Pamela Munster, Md, MD
Hematology & Oncology — Payments: $98,260
Hematology & Oncology $98,260
Dr. Caroline Behler, M.d., M.s, M.D., M.S
Hematology & Oncology — Payments: $64,653
Hematology & Oncology $64,653
David Oh
Hematology & Oncology — Payments: $57,997
Hematology & Oncology $57,997
Dr. Paul Volberding, Md, MD
Hematology & Oncology — Payments: $51,997
Hematology & Oncology $51,997
Dr. Alain Algazi, M.d, M.D
Hematology & Oncology — Payments: $24,175
Hematology & Oncology $24,175
Rebecca Olin, Md, MD
Hematology & Oncology — Payments: $14,579
Hematology & Oncology $14,579